Roche agrees to $1bn deal with Dualitas for bispecific antibody research

Roche and Dualitas Therapeutics have entered a research and licence agreement to develop bispecific antibodies for I&I diseases. Dualitas is set to receive $36.5m upfront and could become eligible for milestone payments. The collaboration will leverage Dualitas’ proximity biology capabilities to produce bispecific antibody therapeutics. Credit: THICHA SATAPITANON / Shutterstock.com. Roche and Dualitas Therapeutics have entered a research collaboration and licence agreement that could reach a potential value of up to $1bn, aiming to discover and develop bispecific antibodies for immunology and inflammation (I&I) diseases. Under this arrangement, Dualitas will use its DualScreen Bispecific Discovery Engine to functionally screen more…

Source: Pharmaceutical Technology